ANG Lifesciences (540694)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Price of ₹50.92 is about 12% below book value of ₹58.10, offering a modest asset cushion if the book is reliable.
• Piotroski F-Score of 5/9 suggests the company is not in acute financial distress.
• Profit growth of 8.48% hints at possible stabilization from a very weak earnings base.
• Small market cap of ₹66 crore means even modest absolute profitability could move per-share metrics meaningfully.

Concerns

• Latest quarter is loss-making: ₹19 crore sales with ₹-5 crore net profit, and annual sales declined 24.26%.
• Negative ROE of -10.59% and ROCE of -4.18% indicate value destruction, so book value may erode further.
• P/E is 0.00 because there are no positive trailing earnings to value.
• No dividend, no promoter holding data, and debt/equity not available make outside assessment difficult.

AI Analysis

Let me apply the same lens I use with any business: what is the durable earning power, and how much am I paying for it? ANG Lifesciences gives me no positive earnings to underwrite. With a market cap of ₹66 crore and latest quarter sales of ₹19 crore that still produced a ₹5 crore loss, this is a company that is currently destroying value. The annual sales decline of 24.26% reinforces that. The reported profit growth of 8.48% is a small consolation, but a near-zero base can produce misleading percentages. Book value is ₹58.10 per share, so the stock at ₹50.92 is priced at 0.88 times book. That looks like an asset play until you notice ROE of -10.59% and ROCE of -4.18%. A book value that earns negative returns is a shrinking asset; the buffer can melt away if losses continue. The Piotroski score of 5 out of 9 is middling and does not tell me the business is recovering. There is no dividend, debt/equity is unavailable, and promoter holding is not disclosed, so an outside shareholder faces a lack of transparency. The 52-week range of ₹17.63 to ₹50.92 shows the stock has already moved up sharply, but price action is not value. A Graham disciple buys a bargain only when assets are real, management is honest, and there is a catalyst. I see no proof of that here. This may one day become a turnaround, but I need to see stable sales, positive net profit, and improving returns on capital before risking our money. For now, the arithmetic does not convince me.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer